Calcitonin Gene-Related Peptide Monoclonal Antibodies: Key Lessons from Real-World Evidence
Brain Sciences · 22.09.2024 · 14 (9) · 948
DOI: 10.3390/brainsci14090948 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Brain Sciences, online erschienen am 22.09.2024. Verfasst von Bianca Orlando und 4 weiteren Autor:innen. Beteiligte Einrichtung: Headache and Pain Unit, IRCCS San Raffaele, Via della Pisana 235, 00163 Rome, Italy. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health (Institutional Funding Ricerca Corrente), IRCCS San Raffaele Roma, Fondazione Italiana Cefalee (FICEF).
Abstract (Originalsprache)
Background
The advent of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway has transformed the management of migraine, offering newfound optimism for clinicians and individuals with episodic migraine (EM) and chronic migraine (CM). While randomized controlled trials (RCTs) have provided crucial insights into the effectiveness and safety profiles of these treatments, their translation into real-world clinical practice remains a challenge.
Objective
This review aims to conduct a comprehensive assessment of real-world studies, offering valuable insights tailored for practical application in clinical settings.
Methods
We conducted a comprehensive literature search in PubMed, SCOPUS, and MEDLINE for real-life studies on erenumab, fremanezumab, and galcanezumab. Abstracts underwent rigorous screening by two reviewers for relevance. Data extraction from selected articles was performed using a standardized form, with verification by a second reviewer. Data synthesis was narrative, following PRISMA guidelines.
Results
Our search included 61 pertinent studies conducted between 2019 and 1 March 2024. Real-world study designs demonstrated notable variability in the selection and inclusion of migraine patients, influenced by factors such as attack frequency, data collection criteria, and primary/secondary objectives. Key findings commonly reported considerable improvements in efficacy outcomes (migraine frequency, analgesic use, pain severity, and disability), high responder rates, and optimal safety and tolerability profiles.
Conclusions
Real-world evidence underscores the role of anti-CGRP mAbs as targeted therapies for both CM and EM patients. The overall results indicate that the effectiveness and tolerability of anti-CGRP mAbs in real-world applications may exceed those observed in RCTs, an extraordinary finding in clinical neurology.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Headache and Pain Unit, IRCCS San Raffaele, Via della Pisana 235, 00163 Rome, Italy.
- San Raffaele University, 00166 Rome, Italy.
ORCID-Profile: Cinzia Aurilia, Piero Barbanti
Förderung
- Italian Ministry of Health (Institutional Funding Ricerca Corrente)
- IRCCS San Raffaele Roma
- Fondazione Italiana Cefalee (FICEF)
Zitieren
APA
Orlando, B., Egeo, G., Aurilia, C., Fiorentini, G., & Barbanti, P. (2024). Calcitonin Gene-Related Peptide Monoclonal Antibodies: Key Lessons from Real-World Evidence. Brain Sciences, 14(9), 948. https://doi.org/10.3390/brainsci14090948
Vancouver
Orlando B, Egeo G, Aurilia C, Fiorentini G, Barbanti P. Calcitonin Gene-Related Peptide Monoclonal Antibodies: Key Lessons from Real-World Evidence. Brain Sciences. 2024;14(9):948. doi:10.3390/brainsci14090948
BibTeX
@article{Orlando2024,
author = {Orlando, Bianca and Egeo, Gabriella and Aurilia, Cinzia and Fiorentini, Giulia and Barbanti, Piero},
title = {Calcitonin Gene-Related Peptide Monoclonal Antibodies: Key Lessons from Real-World Evidence},
journal = {Brain Sciences},
year = {2024},
volume = {14},
number = {9},
pages = {948},
doi = {10.3390/brainsci14090948}
}
EUVIMED